FDA-approved Mounjaro (tirzepatide) is a GLP-1 medication used for treating diabetes in adults who have a body mass index (BMI) over 27, have hypertension or dyslipidemia, or are obese ( BMI over 30)
Lipotropic amino acids (methionine, inositol, choline) activate fat metabolism pathways that B12 alone does not target, making LIPO-C a metabolic support compound rather than a deficiency treatment
Notably, depending on the formulation, Semaglutide is reported to have a particle size ranging from 4 to 3,000 nm in DLS measurements (Li et al., 2024
Patients requiring multifactorial risk management : Individuals with multiple cardiovascular risk factors may benefit from the pleiotropic effects of GLP-1 therapy, including blood pressure reduction, weight loss, and lipid improvements